CPU-118

Main objectives: 1) To evaluate the safety and tolerability of melaleuca tablets in the treatment of patients with advanced malignant solid tumors, and to determine the recommended dose of melaleuca tablets for subsequent clinical trials in patients with advanced malignant solid tumors; 2) To preliminarily evaluate the anti-tumor activity of melaleuca tablets in patients with advanced hepatocellular carcinoma (HCC). Secondary objectives: 1) To evaluate the pharmacokinetic (PK) characteristics of melaleuca tablets in patients with advanced malignant solid tumors; 2) To preliminarily evaluate the anti-tumor activity of melaleuca tablets in patients with other advanced solid tumors except HCC.